New cell therapy trial hopes to tame chronic eye inflammation
Disease control
Not yet recruiting
This early-stage study tests a one-time cell therapy called TRX103 for people with active non-infectious uveitis, a condition causing eye inflammation. Up to 18 adults aged 18-70 will receive the treatment intravenously and be monitored for a year. The main goal is to check safet…
Phase: PHASE1 • Sponsor: Quan Dong Nguyen • Aim: Disease control
Last updated May 14, 2026 12:02 UTC